Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcus Biosciences, Inc.RCUS · Entity 4104 | Chief Accounting Officer | August 21, 2026 | August 24, 2026 |
| Sienna Biopharmaceuticals, Inc.SNNA · Entity 154554 | Chief Financial Officer | October 02, 2019 | October 04, 2019 |
| Unity Biotechnology, Inc.UBX · Entity 77428 | See Remarks | September 13, 2020 | September 15, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcus Biosciences, Inc.
Report date August 21, 2026 · Filed August 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 39,581 |
Last balance in matching sequence
After 2026-08-21 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-08-21 · Exercise / conversion · Acquired 2,827 · Balance 42,408 F1: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2: Includes the unvested portion of the Reporting Person's RSU grants. Row 2 · 2026-08-21 · Sale · Disposed 2,827 · Balance 39,581 F1: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2: Includes the unvested portion of the Reporting Person's RSU grants. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.44 · Expires 2034-01-22 | Direct | 3,073 |
Reported balance
After 2026-08-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-21 · Exercise / conversion · Disposed 2,827 · Balance 3,073 F1: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3: The option becomes exercisable in 48 equal monthly installments after January 1, 2024, subject to the Reporting Person's continued service to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2: Includes the unvested portion of the Reporting Person's RSU grants.
F3: The option becomes exercisable in 48 equal monthly installments after January 1, 2024, subject to the Reporting Person's continued service to the Company.
Sienna Biopharmaceuticals, Inc.
Report date October 02, 2019 · Filed October 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 103,552 |
Reported balance
After 2019-10-02 transaction · row 1
1 source rowRow 1 · 2019-10-02 · Tax withholding · Disposed 2,396 · Balance 103,552 F1: Represents shares otherwise issuable to the Reporting Person that were withheld to satisfy the Issuer's tax withholding obligation upon settlement of restricted stock units. F2: This transaction was executed in multiple trades in prices ranging from $0.225 to $0.2255 inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares otherwise issuable to the Reporting Person that were withheld to satisfy the Issuer's tax withholding obligation upon settlement of restricted stock units.
F2: This transaction was executed in multiple trades in prices ranging from $0.225 to $0.2255 inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Unity Biotechnology, Inc.
Report date September 13, 2020 · Filed September 15, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 135,000 |
Reported balance
After 2020-09-13 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-09-13 · Grant · Acquired 135,000 · Balance 135,000 F1: Represents Restricted Stock Units ("RSUs") one-third of which vests on September 13, 2021 with the remaining RSUs vesting in equal quarterly installments over a two year period thereafter. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Restricted Stock Units ("RSUs") one-third of which vests on September 13, 2021 with the remaining RSUs vesting in equal quarterly installments over a two year period thereafter. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 21, 2026 Filed Aug 24, 2026 21:52 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Exercise / conversionStock Option (right to buy) · Derivative | 2,827 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0001771961-26-000006 · wk-form4_1787608336.xml · derivative · entry 3 Azoy Alexander · CIK 0001771961 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,073 Underlying: Common Stock · 2,827 shares Expires 2034-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · derivative.exercise_date: The option becomes exercisable in 48 equal monthly installments after January 1, 2024, subject to the Reporting Person's continued service to the Company. Read SEC document |
| August 21, 2026 Filed Aug 24, 2026 21:52 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 2,827 | $30.00 | $84,810.00 |
DisclosureSEC source: 0001771961-26-000006 · wk-form4_1787608336.xml · nonDerivative · entry 2 Azoy Alexander · CIK 0001771961 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,581 F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes the unvested portion of the Reporting Person's RSU grants. Read SEC document |
| August 21, 2026 Filed Aug 24, 2026 21:52 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Exercise / conversionCommon Stock | 2,827 | $15.44 | $43,648.88 |
DisclosureSEC source: 0001771961-26-000006 · wk-form4_1787608336.xml · nonDerivative · entry 1 Azoy Alexander · CIK 0001771961 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes the unvested portion of the Reporting Person's RSU grants. Read SEC document |
| June 01, 2026 Filed Jun 1, 2026 23:23 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 2,562 | $25.77 | $66,023.76 |
DisclosureSEC source: 0001771961-26-000004 · wk-form4_1780356235.xml · nonDerivative · entry 1 Azoy Alexander · CIK 0001771961 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,581 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · shares: Consists of 2,562 shares purchased on 5/29/2026 through the Company's Employee Stock Purchase Plan. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.67 to $25.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F4 · balance_after: Includes the unvested portion of the Reporting Person's RSU grants. Read SEC document |
| January 23, 2026 Filed Jan 27, 2026 01:21 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 14,050 | $0.00 Strike: $22.13 | $0.00 |
DisclosureSEC source: 0001771961-26-000002 · wk-form4_1769476880.xml · derivative · entry 2 Azoy Alexander · CIK 0001771961 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,050 Underlying: Common Stock · 14,050 shares Expires 2036-01-22 F3 · derivative.exercise_date: The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 23, 2026 Filed Jan 27, 2026 01:21 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 21,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001771961-26-000002 · wk-form4_1769476880.xml · nonDerivative · entry 1 Azoy Alexander · CIK 0001771961 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,581 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company. F2 · balance_after: Includes the unvested portion of the Reporting Person's RSU grants. Read SEC document |
| December 18, 2025 Filed Dec 18, 2025 22:35 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 4,343 | $22.25 | $96,613.51 |
DisclosureSEC source: 0001771961-25-000014 · wk-form4_1766097326.xml · nonDerivative · entry 3 Azoy Alexander · CIK 0001771961 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,531 F5 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 6, 2025. F6 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.90 to $22.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes the unvested portion of the reporting person's RSU grants. Read SEC document |
| December 17, 2025 Filed Dec 18, 2025 22:35 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 2,113 | $22.16 | $46,823.02 |
DisclosureSEC source: 0001771961-25-000014 · wk-form4_1766097326.xml · nonDerivative · entry 2 Azoy Alexander · CIK 0001771961 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,874 F1 · shares: Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and does not represent a discretionary trade by the reporting person. F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.92 to $22.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes the unvested portion of the reporting person's RSU grants. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 22:35 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 2,376 | $21.88 | $51,997.10 |
DisclosureSEC source: 0001771961-25-000014 · wk-form4_1766097326.xml · nonDerivative · entry 1 Azoy Alexander · CIK 0001771961 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,987 F1 · shares: Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.42 to $22.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes the unvested portion of the reporting person's RSU grants. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 23:09 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Exercise / conversionStock Option (right to buy) · Derivative | 1,900 | $0.00 Strike: $13.33 | $0.00 |
DisclosureSEC source: 0001771961-25-000009 · wk-form4_1764630580.xml · derivative · entry 3 Azoy Alexander · CIK 0001771961 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Stock · 1,900 shares Expires 2035-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: The option becomes exercisable in 48 equal monthly installments after January 1, 2025, subject to the Reporting Person's continued service to the Company. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 23:09 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 1,900 | $26.00 | $49,400.00 |
DisclosureSEC source: 0001771961-25-000009 · wk-form4_1764630580.xml · nonDerivative · entry 2 Azoy Alexander · CIK 0001771961 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,363 F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 23:09 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Exercise / conversionCommon Stock | 1,900 | $13.33 | $25,327.00 |
DisclosureSEC source: 0001771961-25-000009 · wk-form4_1764630580.xml · nonDerivative · entry 1 Azoy Alexander · CIK 0001771961 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 29, 2025 Filed Sep 30, 2025 22:59 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 2,831 | $13.00 | $36,803.00 |
DisclosureSEC source: 0001771961-25-000006 · wk-form4_1759273140.xml · nonDerivative · entry 1 Azoy Alexander · CIK 0001771961 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,363 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 6, 2025. Read SEC document |
| September 05, 2025 Filed Sep 5, 2025 23:48 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 1,579 | $11.88 | $18,758.05 |
DisclosureSEC source: 0001771961-25-000003 · wk-form4_1757116088.xml · nonDerivative · entry 1 Azoy Alexander · CIK 0001771961 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,194 F1 · shares: Consists of 1,579 shares purchased on 5/30/2025 through the Company's Employee Stock Purchase Plan. F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 6, 2025. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.55 to $12.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 21:30 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 11,400 | $0.00 Strike: $13.33 | $0.00 |
DisclosureSEC source: 0001724521-25-000016 · wk-form4_1738013405.xml · derivative · entry 2 Azoy Alexander · CIK 0001771961 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,400 Underlying: Common Stock · 11,400 shares Expires 2035-01-22 F2 · derivative.exercise_date: The option becomes exercisable in 48 equal monthly installments after January 1, 2025, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 21:30 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 17,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001724521-25-000016 · wk-form4_1738013405.xml · nonDerivative · entry 1 Azoy Alexander · CIK 0001771961 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,194 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2025, subject to the Reporting Person's continued service to the Company. Read SEC document |
| December 19, 2024 Filed Dec 20, 2024 21:06 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Disposition to issuerCommon Stock | 3,007 | $15.17 | $45,616.19 |
DisclosureSEC source: 0001724521-24-000187 · wk-form4_1734728787.xml · nonDerivative · entry 1 Azoy Alexander · CIK 0001771961 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,094 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2024. Read SEC document |
| December 15, 2024 Filed Dec 18, 2024 01:36 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Tax withholdingCommon Stock | 2,969 | $16.08 | $47,741.52 |
DisclosureSEC source: 0001724521-24-000179 · wk-form4_1734485761.xml · nonDerivative · entry 1 Azoy Alexander · CIK 0001771961 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,101 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy the applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 21:10 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 201 | $15.32 | $3,079.32 |
DisclosureSEC source: 0001724521-24-000162 · wk-form4_1733346648.xml · nonDerivative · entry 1 Azoy Alexander · CIK 0001771961 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,070 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2024. F2 · shares: Consists of 201 shares purchased on 11/29/2024 through the Company's Employee Stock Purchase Plan. Read SEC document |
| August 13, 2024 Filed Aug 15, 2024 20:45 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 1,357 | $14.97 | $20,314.29 |
DisclosureSEC source: 0001724521-24-000141 · wk-form4_1723754700.xml · nonDerivative · entry 1 Azoy Alexander · CIK 0001771961 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,070 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2024. F2 · shares: Consists of 1,357 shares purchased on 5/31/2024 through the Company's Employee Stock Purchase Plan. Read SEC document |
| January 23, 2024 Filed Jan 26, 2024 00:39 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 5,900 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0001724521-24-000028 · wk-form4_1706229580.xml · derivative · entry 2 Azoy Alexander · CIK 0001771961 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,900 Underlying: Common Stock · 5,900 shares Expires 2034-01-22 F2 · derivative.exercise_date: The option becomes exercisable in 48 equal monthly installments after January 1, 2024, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 23, 2024 Filed Jan 26, 2024 00:39 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 8,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001724521-24-000028 · wk-form4_1706229580.xml · nonDerivative · entry 1 Azoy Alexander · CIK 0001771961 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,070 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2024, subject to the Reporting Person's continued service to the Company. Read SEC document |
| December 20, 2023 Filed Dec 22, 2023 21:06 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Disposition to issuerCommon Stock | 68 | $18.21 | $1,238.28 |
DisclosureSEC source: 0001724521-23-000073 · wk-form4_1703279185.xml · nonDerivative · entry 1 Azoy Alexander · CIK 0001771961 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,220 F1 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 30, 2023. Read SEC document |
| December 19, 2023 Filed Dec 20, 2023 21:10 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Disposition to issuerCommon Stock | 661 | $18.09 | $11,957.49 |
DisclosureSEC source: 0001724521-23-000068 · wk-form4_1703106610.xml · nonDerivative · entry 2 Azoy Alexander · CIK 0001771961 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,288 F1 · shares: Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.78 to $18.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 21:10 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Disposition to issuerCommon Stock | 647 | $17.74 | $11,477.78 |
DisclosureSEC source: 0001724521-23-000068 · wk-form4_1703106610.xml · nonDerivative · entry 1 Azoy Alexander · CIK 0001771961 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,949 F1 · shares: Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.45 to $17.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:28 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 282 | $14.95 | $4,215.90 |
DisclosureSEC source: 0001724521-23-000024 · wk-form4_1701811666.xml · nonDerivative · entry 1 Azoy Alexander · CIK 0001771961 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,596 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 30, 2023. F2 · shares: Consists of 282 shares purchased on 11/30/2023 through the Company's Employee Stock Purchase Plan. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 20:05 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | SaleCommon Stock | 1,018 | $20.41 | $20,777.38 |
DisclosureSEC source: 0001209191-23-040964 · doc4.xml · nonDerivative · entry 1 Azoy Alexander · CIK 0001771961 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,596 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 30, 2023. Read SEC document |
| September 13, 2020 Filed Sep 15, 2020 20:56 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantCommon Stock, $0.0001 par value | 135,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025180 · doc4.xml · nonDerivative · entry 1 Azoy Alexander · CIK 0001771961 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 F1 · shares: Represents Restricted Stock Units ("RSUs") one-third of which vests on September 13, 2021 with the remaining RSUs vesting in equal quarterly installments over a two year period thereafter. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. F1 · balance_after: Represents Restricted Stock Units ("RSUs") one-third of which vests on September 13, 2021 with the remaining RSUs vesting in equal quarterly installments over a two year period thereafter. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Read SEC document |
| October 02, 2019 Filed Oct 4, 2019 14:10 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | Tax withholdingCommon Stock | 2,396 | $0.23 | $551.08 |
DisclosureSEC source: 0001562180-19-005117 · primarydocument.xml · nonDerivative · entry 1 Azoy Alexander · CIK 0001771961 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,552 F1 · shares: Represents shares otherwise issuable to the Reporting Person that were withheld to satisfy the Issuer's tax withholding obligation upon settlement of restricted stock units. F2 · price: This transaction was executed in multiple trades in prices ranging from $0.225 to $0.2255 inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 16:42 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | GrantStock Options (Right to buy) · Derivative | 20,000 | Not disclosed Strike: $0.71 | Not disclosed |
DisclosureSEC source: 0001562180-19-004218 · primarydocument.xml · derivative · entry 11 Azoy Alexander · CIK 0001771961 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-04-01 F2 · kind: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F2 · price: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F5 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on October 1,2019, twenty-five percent (25%) of the shares vest and become exercisable on April 1, 2020, and the remaining shares vest and become exercisable in 12 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 16:42 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | GrantStock Options (Right to buy) · Derivative | 8,750 | Not disclosed Strike: $0.71 | Not disclosed |
DisclosureSEC source: 0001562180-19-004218 · primarydocument.xml · derivative · entry 10 Azoy Alexander · CIK 0001771961 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,750 Underlying: Common Stock · 8,750 shares Expires 2029-01-01 F2 · kind: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F2 · price: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F7 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on July 1,2019, twenty-five percent (25%) of the shares vest and become exercisable on January 1, 2020, and the remaining shares vest and become exercisable in 12 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 16:42 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | GrantStock Options (Right to buy) · Derivative | 8,750 | Not disclosed Strike: $0.71 | Not disclosed |
DisclosureSEC source: 0001562180-19-004218 · primarydocument.xml · derivative · entry 9 Azoy Alexander · CIK 0001771961 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,750 Underlying: Common Stock · 8,750 shares Expires 2029-01-01 F2 · kind: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F2 · price: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F6 · derivative.exercise_date: Twenty percent (20%) of the shares subject to the option vest and become exercisable upon satisfaction of one performance-based milestone, forty percent (40%) of the shares vest and become exercisable upon satisfaction of a second performance-based milestone, and the remaining forty percent (40%) of the shares vest and become exercisable upon satisfaction of a third performance-based milestone, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 16:42 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | GrantStock Options (Right to buy) · Derivative | 5,600 | Not disclosed Strike: $0.71 | Not disclosed |
DisclosureSEC source: 0001562180-19-004218 · primarydocument.xml · derivative · entry 8 Azoy Alexander · CIK 0001771961 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,600 Underlying: Common Stock · 5,600 shares Expires 2028-06-01 F2 · kind: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F2 · price: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F4 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the option vest and become exercisable on the first anniversary measured from June 1, 2018, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 16:42 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | GrantStock Options (Right to buy) · Derivative | 25,000 | Not disclosed Strike: $0.71 | Not disclosed |
DisclosureSEC source: 0001562180-19-004218 · primarydocument.xml · derivative · entry 7 Azoy Alexander · CIK 0001771961 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-12-01 F2 · kind: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F2 · price: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F3 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on the first anniversary measured from December 1, 2017, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 16:42 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | Disposition to issuerStock Options (Right to buy) · Derivative | 8,750 | Not disclosed Strike: $2.32 | Not disclosed |
DisclosureSEC source: 0001562180-19-004218 · primarydocument.xml · derivative · entry 6 Azoy Alexander · CIK 0001771961 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,750 shares Expires 2029-01-01 F2 · kind: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F2 · price: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F7 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on July 1,2019, twenty-five percent (25%) of the shares vest and become exercisable on January 1, 2020, and the remaining shares vest and become exercisable in 12 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 16:42 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | Disposition to issuerStock Options (Right to buy) · Derivative | 8,750 | Not disclosed Strike: $2.32 | Not disclosed |
DisclosureSEC source: 0001562180-19-004218 · primarydocument.xml · derivative · entry 5 Azoy Alexander · CIK 0001771961 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,750 shares Expires 2029-01-01 F2 · kind: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F2 · price: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F6 · derivative.exercise_date: Twenty percent (20%) of the shares subject to the option vest and become exercisable upon satisfaction of one performance-based milestone, forty percent (40%) of the shares vest and become exercisable upon satisfaction of a second performance-based milestone, and the remaining forty percent (40%) of the shares vest and become exercisable upon satisfaction of a third performance-based milestone, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 16:42 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | Disposition to issuerStock Options (Right to buy) · Derivative | 20,000 | Not disclosed Strike: $2.37 | Not disclosed |
DisclosureSEC source: 0001562180-19-004218 · primarydocument.xml · derivative · entry 4 Azoy Alexander · CIK 0001771961 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2029-04-01 F2 · kind: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F2 · price: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F5 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on October 1,2019, twenty-five percent (25%) of the shares vest and become exercisable on April 1, 2020, and the remaining shares vest and become exercisable in 12 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 16:42 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | Disposition to issuerStock Options (Right to buy) · Derivative | 5,600 | Not disclosed Strike: $15.08 | Not disclosed |
DisclosureSEC source: 0001562180-19-004218 · primarydocument.xml · derivative · entry 3 Azoy Alexander · CIK 0001771961 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,600 shares Expires 2028-06-01 F2 · kind: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F2 · price: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F4 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the option vest and become exercisable on the first anniversary measured from June 1, 2018, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 16:42 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | Disposition to issuerStock Options (Right to buy) · Derivative | 25,000 | Not disclosed Strike: $20.19 | Not disclosed |
DisclosureSEC source: 0001562180-19-004218 · primarydocument.xml · derivative · entry 2 Azoy Alexander · CIK 0001771961 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2027-12-01 F2 · kind: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F2 · price: The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options. F3 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on the first anniversary measured from December 1, 2017, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 16:42 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | GrantCommon Stock | 70,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-19-004218 · primarydocument.xml · nonDerivative · entry 1 Azoy Alexander · CIK 0001771961 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,948 F1 · price: Award of restricted stock units ("RSUs") granted under the Issuer's 2017 Incentive Award Plan. Each RSU entitles the Reporting Person to receive one share of Issuer common stock upon vesting. The award vests as to fifty percent (50%) of the total number of RSUs on February 6, 2020, twenty-five percent (25%) of the total number of RSUs on August 6, 2020, and the remaining twenty-five percent (25%) of the total number of RSUs on February 6, 2021, in each case, subject to the Reporting Person's continued employment or service relationship with the Issuer through the applicable vesting date. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 13:36 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | Tax withholdingCommon Stock | 1,552 | $0.76 | $1,179.52 |
DisclosureSEC source: 0001562180-19-003849 · primarydocument.xml · nonDerivative · entry 1 Azoy Alexander · CIK 0001771961 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,948 F1 · shares: Represents shares otherwise issuable to the Reporting Person that were withheld to satisfy the Issuer's tax withholding obligation upon settlement of restricted stock units. F2 · price: This transaction was executed in multiple trades in prices ranging from $0.72 to $0.83, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 17:44 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | GrantStock Options (Right to buy) · Derivative | 20,000 | $0.00 Strike: $2.37 | $0.00 |
DisclosureSEC source: 0001562180-19-002196 · primarydocument.xml · derivative · entry 2 Azoy Alexander · CIK 0001771961 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-04-01 F3 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on October 1, 2019, twenty-five percent (25%) of the shares vest and become exercisable on April 1, 2020, and the remaining shares vest and become exercisable in 12 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 17:44 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | GrantCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-19-002196 · primarydocument.xml · nonDerivative · entry 1 Azoy Alexander · CIK 0001771961 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 F1 · price: Award of restricted stock units ("RSUs") granted under the Issuer's 2017 Incentive Award Plan. Each RSU entitles the Reporting Person to receive one share of Issuer's common stock upon vesting. The award vests as to twenty-five percent (25%) of the total number of RSUs on October 1, 2019, twenty-five percent (25%) of the total number of RSUs on April 1, 2020, and the remaining fifty percent (50%) of the total number of RSUs on the second anniversary, in each case, subject to the Reporting Person's continued employment or service relationship with the Issuer through the applicable vesting date. F2 · balance_after: Includes 17,500 shares of the Issuer's common stock underlying the RSUs awarded. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.